Shares of Circor International Inc. CIR rallied 4.9% toward a six-year high in morning trading Wednesday, but pared an earlier intraday gain of 6.7%, after KKR & Co. Inc. KKR affirmed its intention to buy the flow-control-products company. KKR’s announcement comes after private-equity firm Arcline Investment Management LP submitted a $57-a-share cash bid to buy Circor, which is about 12% KKR’s agreed-upon amended bid of $51 a share. KKR’s stock fell 0.9% in morning trading.
KKR affirmed its intention to buy the flow-control-products company. KKR’s announcement comes after private-equity firm Arcline Investment Management LP submitted a $57-a-share cash bid to buy Circor, which is about 12% KKR’s agreed-upon amended bid of $51 a share. KKR’s stock fell 0.9% in morning trading. “KKR is confident that its transaction to acquire Circor maximizes shareholder value while minimizing regulatory, market, and industry risks,” KKR said in a statement.
Coin Coin Latest News, Coin Coin Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Circor stock rallies toward 5-year high after merger deal with KKR was improvedShares of Circor International Inc. surged 4.6% toward a five-year high in premarket trading Tuesday, after the flow-control-products company agreed to an...
Source: MarketWatch - 🏆 3. / 97 Read more »
Hawaiian Airlines stock tumbles, while shares of its airline peers rallyShares of Hawaiian Holdings Inc. the parent of Hawaiian Airlines, dove 9.3% in afternoon trading Monday, to buck the rally in its air-carrier peers. The...
Source: MarketWatch - 🏆 3. / 97 Read more »
FibroGen's lung disease drug fails late-stage trial, shares tankFibroGen said on Monday its experimental drug for a chronic lung disease failed to significantly slow the decline in a key measure of lung function in a late-stage study, sending the drugmaker's shares to a record low in morning trading.
Source: Reuters - 🏆 2. / 97 Read more »